US Biosimilars Market Will Benefit From Surge In Launches
Q&A With AmerisourceBergen's Senior Director Of Biosimilars, Sean McGowan
A wave of recent biosimilar launches in the US has provided multi-source competition on several major brands and stands to boost the country’s biosimilars market, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen.
You may also be interested in...
With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.